Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet‐induced obese and leptin‐deficient rodents
James L. Trevaskis, Jonathan D. Roth(Rutgers, The State University of New Jersey), Carrie Wittmer(Amplyx Pharmaceuticals (United States)), Jennifer Athanacio(Amplyx Pharmaceuticals (United States)), Lawrence J. D’Souza, P. S. Griffin, Krystyna Tatarkiewicz(Amplyx Pharmaceuticals (United States)), Bruce Forood, David G. Parkes(Amplyx Pharmaceuticals (United States)), Changqi Sun, Manoj Samant, Chenmei Teng, Y. Wang
Cited by 59
Related Papers
Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies
|Proceedings of the National Academy of Sciences|2008|433
Amylin: Pharmacology, Physiology, and Clinical Potential
|Pharmacological Reviews|2015|395
Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment
|American Journal of Physiology-Gastrointestinal and Liver Physiology|2013|294
Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
|American Journal of Physiology-Gastrointestinal and Liver Physiology|2012|278